WO2005025600A1 - 接着性を有する細胞の末梢血への動員を阻害する薬剤 - Google Patents
接着性を有する細胞の末梢血への動員を阻害する薬剤 Download PDFInfo
- Publication number
- WO2005025600A1 WO2005025600A1 PCT/JP2004/013593 JP2004013593W WO2005025600A1 WO 2005025600 A1 WO2005025600 A1 WO 2005025600A1 JP 2004013593 W JP2004013593 W JP 2004013593W WO 2005025600 A1 WO2005025600 A1 WO 2005025600A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- scgf
- cells
- stem cell
- agent
- active ingredient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a drug
- SCGF hematopoietic stem cell growth factor
- '' SCGF is a factor isolated and identified from the myeloid cell line KPB-M15 established from patients with chronic myelogenous leukemia (Hiraoka A., Ohkubo T, Fukuda M, Cancer Res. 1987; 47: 5025-5030 .)
- SCGF is a 29-kDa protein without N-glycans and belongs to the family of C-type lectins (HiraokaA, SugimotoA, Seki Tet al. Proc. Natl. Acad. Sci. USA 1997; 94: 7577-7582 .)
- SCGF In situ hybridization analysis has shown that the SCGF gene is expressed in bone and bone marrow (Hiraoka A, Yano K, Kagami N et al. Hematol. J. 2001; 2: 307-315.). SCGF alone does not have hematopoietic cell colony-promoting activity, but erythropoietin can be combined with GM-CSF (Granulocyte-Macrophage-colony-stimulating-fator) to produce erythroid and granulocyte cells. 'A macrophage colony formation promoting activity is observed (Hiraoka A, Sugimoto A, Seki T et al. Proc. Natl. Acad. Sci.
- GM-CSF Granulocyte-Macrophage-colony-stimulating-fator
- stem cells and progenitor cells have been observed in various adult tissues, and these stem cells and progenitor cells are considered to be responsible for pathological and physiological regeneration of tissues and organs.
- angiogenesis in the development of malignant tumors (Sussman LK, Upalakalin JN, Roberts MJ, Kocher 0, and Benjamin LE. Cancer Biol. Ther. 2003; 2: 255-6.)
- Arteriosclerosis It has been shown that bone marrow stem cells are involved in vascular occlusion in rats (Sata M, Saiura A, Kunisato A, To jo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, and Nagai R. Nat.
- An object of the present invention is to provide a drug which inhibits the recruitment of adherent cells, such as bone marrow stem cells or progenitor cells, containing SCGF as an active ingredient to peripheral blood, and uses thereof.
- adherent cells such as bone marrow stem cells or progenitor cells
- SCGF as an active ingredient to peripheral blood
- SCGF hematopoietic stem cell growth factor
- SCGF hematopoietic stem cell growth factor
- SCGF hematopoietic stem cell growth factor
- SCGF hematopoietic stem cell growth factor
- SCGF chemically modified hematopoietic stem cell growth factor
- progenitor cells are cells selected from the group consisting of vascular progenitor cells, monocyte, granulocyte common progenitor cells, and smooth muscle progenitor cells.
- An angiogenesis inhibitor comprising the drug according to any one of (1) to (8) above as an active ingredient.
- An inhibitor of granulocyte / monogenesis comprising the drug according to any one of (1) to (8) above as an active ingredient.
- An antitumor agent comprising the drug according to any one of (1) to (8) as an active ingredient.
- An anti-inflammatory agent comprising the drug according to any one of (1) to (8) as an active ingredient.
- a therapeutic drug for arteriosclerosis comprising the drug according to any one of the above (1) to (8) as an active ingredient.
- a therapeutic agent for a disease in which the pathogenicity S progresses due to abnormal angiogenesis comprising the agent according to any one of (1) to (8) above as an active ingredient.
- the disease whose disease state progresses due to abnormal angiogenesis is a disease selected from the group consisting of solid tumor growth or metastasis formation, rheumatoid arthritis, diabetic retinopathy, prematurity retinopathy, and psoriasis. 14) The therapeutic agent as described above.
- a method for inhibiting recruitment of adherent cells to peripheral blood which comprises administering hematopoietic stem cell growth factor (SCGF).
- SCGF hematopoietic stem cell growth factor
- SCGF hematopoietic stem cell growth factor
- polypeptide comprising the amino acid sequence of SEQ ID NO: 1 with one or more amino acids deleted, substituted or added, and having hematopoietic stem cell proliferation activity
- polypeptide comprising an amino acid sequence having at least 60% homology with the amino acid sequence described in SEQ ID NO: 1 and having hematopoietic stem cell proliferation activity
- the polypeptide of the present invention is a polypeptide having hematopoietic stem cell proliferation activity.
- the polypeptides described in (2) to (4) above may have substantially the same activity as the polypeptide described in (1) above. Quantitative factors such as molecular weight may be different from the polypeptide described in (1).
- a polypeptide comprising an amino acid sequence in which one or more amino acids have been deleted, substituted or added in the amino acid sequence described in SEQ ID NO: 1 and having hematopoietic stem cell proliferating activity is obtained by Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1989) (hereinafter abbreviated as Molecular 'Cloning 2nd Edition), CurrentProtocols in Molecular Biology, iohn Wiley & Sons (1987-1997) ⁇ , abbreviated as “ology”), Nucleic Acids Research, 10, 6487 (1982), Proc. Natl. Acad. Sci. USA, 79, 6409 (1982), Gene, 34, 315 (1985), Nucleic Acids Research, 13 Natl. Acad.
- the number of amino acids to be deleted, substituted or added is not particularly limited, it is a number that can be deleted, substituted or added by a well-known method such as the above-described site-specific mutation method, and is one to several tens. , Preferably:! -20, more preferably 1-10, and even more preferably 1-5.
- SCGF consists of an amino acid sequence having homology to the amino acid sequence described in SEQ ID NO: 1 when BLAST (Basic Local Alignment Search Tool) is used to search for amino acid sequence homology with SCGF. , 60%, preferably 80%, more preferably 90%, particularly preferably 95% or more.
- the amino acid in the amino acid sequence of SCGF may be changed by substitution, deletion, addition or insertion as compared with the amino acid sequence of SCGF.
- the SCGF used in the present invention may be chemically modified.
- Examples of the method of chemical modification include the method described in W00O / 51626, etc., and SCGF modified with polyethylene glycol (PEG) or the like is also included in the SCGF used in the present invention.
- PEG polyethylene glycol
- tissue cells in the present invention refers to cells having the property of adhering to tissues or cells such as bone marrow and blood vessels, and specifically includes adult pluripotent cells.
- An adult pluripotent stem thread H vesicle refers to a stem cell that exists in each tissue in a living body and can become various mature cells.
- Adhesive pluripotent stem cells, progenitor cells, and the like present in bone marrow are also included as the cells having adhesive properties of the present invention.
- the progenitor cells include vascular progenitor cells (hereinafter also referred to as EPC), monocyte / granulocyte common progenitor cells, smooth muscle progenitor cells, and the like.
- Recruitment of adherent cells to peripheral blood is identified by collecting peripheral blood-derived cells by centrifugation and then selectively cultivating only adherent cells using a culture dish for culturing adherent cells. can do.
- the drug of the present invention inhibits the recruitment of cells having adhesion 'i'fe to peripheral blood, thereby inhibiting angiogenesis, monocytes / granulogenesis, tissue inflammation or tumor formation, etc.
- Diseases whose pathology progresses due to abnormal angiogenesis include solid tumor growth or metastasis, rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, and psoriasis.
- the agent of the present invention can be administered alone as a therapeutic agent, it is usually mixed with one or more pharmacologically acceptable carriers and is well known in the pharmaceutical arts. It is desirable to provide it as a pharmaceutical preparation manufactured by any method.
- oral administration or parenteral administration such as buccal, intratracheal, rectal, intramuscular, subcutaneous, intradermal or intravenous administration. And preferably intramuscular, subcutaneous, intradermal, intravenous or intratracheal administration.
- parenteral administration such as buccal, intratracheal, rectal, intramuscular, subcutaneous, intradermal or intravenous administration.
- intramuscular, subcutaneous, intradermal, intravenous or intratracheal administration examples include tablets, capsules, granules, injections, ointments, tapes, inhalants such as dry powder and aerosol.
- excipients such as lactose, disintegrators such as starch, lubricants such as magnesium stearate, binders such as hydroxypropylcellulose, surfactants such as fatty acid esters, A plasticizer such as glycerin can be used.
- Formulations suitable for intramuscular, subcutaneous, intradermal, intravenous or intratracheal administration include injections, sprays and the like.
- an injection for example, water, physiological saline, vegetable oil such as soybean oil, a solvent, a soluble agent, a isotonic agent, a preservative, an antioxidant and the like can be used.
- Inhalants are prepared using SCGF itself or a carrier that does not irritate the oral and respiratory mucosa of the recipient, disperses SCGF as fine particles, and facilitates absorption.
- Specific examples of the carrier include lactose, dariserin and the like.
- preparations such as aerosols and dry powders are possible.
- the components exemplified as additives in oral preparations can be added.
- the dose or frequency of administration varies depending on the desired therapeutic effect, administration method, treatment period, age, body weight, etc., but it is usually recommended that adults be administered at a dose of 0.01 g / kg to 10 mg / kg per day. It is good.
- Example 1 Effect of SCGF on Matrigel Transplant-Induced Angiogenesis
- mice Five to ten weeks old C57BL / 6J mice (CLEA Japan) were subcutaneously implanted with 500 Matrigel, and 5 At, g human SCGF was administered daily for 7 days. Seven days later, the transplanted Matrigel was excised, fixed with 4% paraformaldehyde, and stained with an anti-mouse CD31 antibody, a marker for vascular endothelium.
- B16 melanoma cells 1.5 to 10 6 B16 melanoma cells were implanted subcutaneously into 8- to 10-week-old C57BL / 6J mice, and daily administration of 5 g of human SCGF was continued for 21 days.
- bone marrow cells were extracted from the femur.
- bone marrow mononuclear cells were obtained by density gradient centrifugation using Histopaque 1038s (manufactured by Sigma).
- Histopaque 1038s manufactured by Sigma.
- the chemotaxis of bone marrow mononuclear cells to SCGF was analyzed using a Boyden chamber and a Transwell 1 chamber (both manufactured by Corning Center).
- mice 8- to 10-week-old C57BL / 6J mice were administered 5 g of human SCGF daily for 1, 4 and 7 days, respectively.
- the target mouse was anesthetized with bentoparpital, and whole blood was collected from the heart with an injection needle coated with ⁇ ' ⁇ / ml heparin.
- mouse blood without human SCGF was also collected. A part of the obtained blood was used for the FACS analysis shown in Example 5 after hemolysis, and the remaining blood was used for the following analysis by EPC culture.
- Mononuclear cells were obtained by using Histopaque 1083 (Sigma) as blood. After concentrating all peripheral blood-derived mononuclear cells in one mouse to a volume of 500/1, Lab Tek 4-well slide glass (Nalge) coated with rat-derived vitronectin (Sigma) Nunc Co.) charged to cultured for 7 days 37 ° C5% C0 2 incubator foremost on the go. The obtained cells were stained with acetyl LDL-Dil label (Biomedical Technology) and isolectinB4 lectin (Vector Lab), and EPC was identified under a fluorescence microscope. Table 2 shows the results.
- Example 7 After hemolysis of the blood obtained in Example 7, 1% BSA (bovine serum albumin), washed with Hank 's Balanced Salt Solution containing 0.01% NaN 3 (HBSS), were ice-cooled for 30 minutes in mouse serum. The cells were stained with an anti-mouse / rat flkl monoclonal antibody (Pharaingen) or a biotin-labeled anti-mouse CD34 antibody (Pharmingen) labeled with phycoerythrin (PE). Cells stained with the antibody were analyzed using Facstar (Becton Dickinson). Table 3 shows the results.
- BSA bovine serum albumin
- Table 3 1 Number of CD34 or flkl-positive cells in 1 ml of peripheral blood of each mouse
- HMVECs Human microvacular endothelial cells
- HUVECs human umbilical vein endothelial cells
- - using 2 medium (Clonet ics Co.) were cultured in 37 ° C7_nichi ⁇ 5% C0 2 incubator within one were to determine cell density by MTS Atsusi. Table 4 shows the results. Table 4
- mononuclear cells include bone marrow stem cells, EPC, and the like.
- Example 8 Effect of SCGF on migration of vascular endothelial cells
- HMVECs, HUVECs and human EPC cultured for 7 days were analyzed using a Boyden chamber and a Transwell chamber.
- the membrane used to separate the two champers is a polycarbonate membrane that has been coated with 0.1% gelatin and S / zg / ml human fibronectin and then dried.
- the cells were suspended in EBM-2 medium containing 0.1% BSA to a cell density of 1 ⁇ 10V100 n1, and injected into the top of the champer.
- the lower portion of the chamber one was allowed to stand at 0, 1, 10, 100 5 % C0 2 incubator ng / ml concentration of human SCGF respectively turned to 6 hours 3 7 ° C.
- the migration ability was determined by fixing the polycarbonate membrane with 100% methanol, washing with water, treating with a Vec tashield mount manufactured by Vector Lab. Inc. containing DAPI, treating with media, and mounting on a slide glass. (Olympus) and the number of cells was analyzed by Photoshop to measure. Table 6 shows the results.
- Example 9 Effect of SCGF on luminal formation of HMVECs and HUVECs '' 1 ⁇ 10 5 HUVECs or HMVECs were suspended in 501 EBM-2 medium containing SCGF, mixed with 501 Matrigel, and spread on 96-well culture dishes. After incubation at 13 hours 37 ° C 5% C0 2 in Kyubeta one, were counted vessel-like tube formed per Ueru under a microscope. The presence of a blood vessel-like tube indicates lumen formation. Table 7 shows the results.
- Table 9 shows the results of the blood image analysis. Table 9 Neutrophils Monocytes Eosinophils Basophils.
- SCGF-administered group 1.20.10.10.1 As a result, a decrease in the number of neutrophils and monocytes, which are a type of granulocytes, among leukocytes was confirmed. These results indicate that long-term administration of SCGF inhibits the recruitment of monocyte / granulocyte progenitor cells (GMP) to peripheral blood. '
- the agent of the present invention that inhibits the recruitment of adherent cells such as bone marrow stem cells or progenitor cells containing the SCGF as an active ingredient into peripheral blood, abnormalities in blood vessel formation including cancer As a result, it becomes possible to treat diseases in which the disease state progresses and diseases such as arteriosclerosis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005513975A JPWO2005025600A1 (ja) | 2003-09-11 | 2004-09-10 | 接着性を有する細胞の末梢血への動員を阻害する薬剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003320054 | 2003-09-11 | ||
JP2003-320054 | 2003-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005025600A1 true WO2005025600A1 (ja) | 2005-03-24 |
Family
ID=34308593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/013593 WO2005025600A1 (ja) | 2003-09-11 | 2004-09-10 | 接着性を有する細胞の末梢血への動員を阻害する薬剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2005025600A1 (ja) |
WO (1) | WO2005025600A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101810191B1 (ko) * | 2016-09-21 | 2017-12-19 | 연세대학교 산학협력단 | 세포 접착의 저해를 위한 줄기세포 성장 인자 또는 그의 단편의 용도 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62223126A (ja) * | 1986-03-25 | 1987-10-01 | Sankyo Co Ltd | 血液幹細胞成長因子 |
WO2000051626A1 (fr) * | 1999-03-01 | 2000-09-08 | Kyowa Hakko Kogyo Co., Ltd. | Preparations de g-csf modifiees chimiquement |
JP2003009854A (ja) * | 2001-04-09 | 2003-01-14 | Kyowa Hakko Kogyo Co Ltd | エンブリオイドボディ形成方法及びその用途 |
-
2004
- 2004-09-10 JP JP2005513975A patent/JPWO2005025600A1/ja active Pending
- 2004-09-10 WO PCT/JP2004/013593 patent/WO2005025600A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62223126A (ja) * | 1986-03-25 | 1987-10-01 | Sankyo Co Ltd | 血液幹細胞成長因子 |
WO2000051626A1 (fr) * | 1999-03-01 | 2000-09-08 | Kyowa Hakko Kogyo Co., Ltd. | Preparations de g-csf modifiees chimiquement |
JP2003009854A (ja) * | 2001-04-09 | 2003-01-14 | Kyowa Hakko Kogyo Co Ltd | エンブリオイドボディ形成方法及びその用途 |
Non-Patent Citations (1)
Title |
---|
KITAMURA K.: "Cytokines", BIOTHERAPY, vol. 11, no. 6, 1997, pages 717 - 727, XP002985731 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101810191B1 (ko) * | 2016-09-21 | 2017-12-19 | 연세대학교 산학협력단 | 세포 접착의 저해를 위한 줄기세포 성장 인자 또는 그의 단편의 용도 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005025600A1 (ja) | 2006-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dexter et al. | Stromal cells in haemopoiesis | |
JP4672370B2 (ja) | 虚血の細胞ベースの治療 | |
Li et al. | CXCR4 positive bone mesenchymal stem cells migrate to human endothelial cell stimulated by ox-LDL via SDF-1α/CXCR4 signaling axis | |
Gronthos et al. | The biology and application of human bone marrow stromal cell precursors | |
Gordon et al. | Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony‐stimulating factor | |
EP1028737B1 (en) | Human mesenchymal stem cells from peripheral blood | |
Bachetti et al. | Endothelial cells in culture: a model for studying vascular functions | |
US7435718B2 (en) | CXCR4 antagonist treatment of hematopoietic cells | |
US20080226612A1 (en) | Compositions of Cells Enriched for Combinations of Various Stem and Progenitor Cell Populations, Methods of Use Thereof and Methods of Private Banking Thereof | |
TW201130977A (en) | Mesenchymal stem cells (MSCs) isolated from mobilized peripheral blood | |
JPWO2006090882A1 (ja) | 血管内皮前駆細胞の生体外増幅方法 | |
WO2001021766A9 (en) | Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells | |
MXPA06006706A (es) | Celulas madre. | |
JPWO2006093172A1 (ja) | 成体幹細胞の体外増幅方法 | |
EP3336176A1 (en) | Improved umbilical cord-derived adhesive stem cells, preparation method therefor, and use thereof | |
WO1998001151A1 (fr) | Nouvelle utilisation de la famille mk comme facteur hematopoietique | |
AU2006321172A1 (en) | Methods of improving stem cell homing and engraftment | |
US20070053884A1 (en) | Novel adult tissue-derived stem cell and use thereof | |
JPWO2020045547A1 (ja) | 線維芽細胞の製造方法及びg−csf陽性線維芽細胞集団 | |
JP2007520462A (ja) | ヒト臍帯血由来多能性細胞の疾患の処置のための使用方法 | |
KR100222274B1 (ko) | 결합되지 않은 mpl 수용체를 사용하여 혈소판 생산을 자극하기 위한 조성물 및 방법 | |
Kannourakis et al. | Proliferative properties of unfractionated, purified, and single cell human progenitor populations stimulated by recombinant human interleukin-3 | |
US20220411761A1 (en) | Fibroblast having enhanced erythropoietin production ability | |
EP1707625A1 (en) | Process for producing hematopoietic stem cells or vascular endothelial precursor cells | |
Zoellner et al. | Human arterial smooth muscle cells synthesize granulocyte colony-stimulating factor in response to interleukin-1 alpha and tumor necrosis factor-alpha |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005513975 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |